The activated RAS/RAF cascade plays a crucial role in lung cancer, but is also known to induce cellular senescence, a major barrier imposed on tumor cells early in tumorigenesis. MYC is a key factor in suppression of RAS/BRAF V600E -induced senescence in vitro. However, it is still unclear whether MYC has the same role during tumor development in vivo. to carcinoma progression. This suggests that senescence suppression by MYC is a discrete step in tumor development important for sustained tumor growth but preceding malignant transformation and that additional oncogenic events are required for carcinoma development and metastasis. These findings contribute to our understanding of the neoplastic transformation process, with implications for future treatment strategies. Cancer Res; 74(16); 4222-9. Ó2014 AACR.
Introduction
Lung cancer is a leading cause of cancer-related death worldwide. Recent genome-wide analysis of driver mutations in non-small cell lung cancers have identified BRAF mutations in 9% of the pulmonary adenocarcinoma subset, with V600E (2%-3%) as the most common (1), correlating with poor prognosis (2) . BRAF encodes for a Ser/Thr kinase playing a central role as a RAS effector in the RAS-RAF-MAPK signaling pathway, which connects extracellular signals to transcriptional regulation of genes involved in proliferation and cancer development. At least 25% of all mutations in pulmonary adenocarcinoma target this pathway (1) . Another central player in tumorigenesis is the transcription factor MYC, which is rearranged and/or overexpressed in over half of human cancers (3), including lung adenocarcinomas where it is found amplified in 30% of cases (1) , correlating with poor prognosis (4) . Mutated, activated RAS or BRAF is known to trigger oncogene-induced senescence (OIS) in preneoplastic lesions in lung adenomas (5, 6) . Cellular senescence is a state of irreversible proliferation arrest, which together with apoptosis forms two of the main barriers against tumor development and usually relies on the p53/CDKN1A (p21 CIP1 ) and CDKN2A (p16 INK4A )/pRB tumor suppressor pathways (6). We and others have shown that the MYC oncogene suppresses RAS/BRAF-induced senescence in normal primary fibroblasts and in tumor cells in vitro (7, 8) , although it can also induce OIS under certain conditions (6, 9) . However, whether it plays a role in senescence suppression in vivo has not yet been demonstrated. To address this question, we utilized a mouse model of BRAF V600E -induced lung adenoma characterized by prominent senescence-like growth arrest (5), intercrossed with mice containing a regulatable MycER allele (10) . Our results show that MYC synergizes with BRAF V600E in lung tumorigenesis by suppressing the senescence-like state, correlating with increased number and size of tumors with elevated proliferative capacity, resulting in reduced survival of the compound mice.
Materials and Methods

Mice
All animal protocols in this study were approved by the ethical committee of the Swedish Board of Agriculture. Fig.  S1A ). Monitoring of adenoma onset was carried out as described previously (5, 10) . Animals were euthanized at specific time points or upon display of visible signs of disease.
Adenoviral Cre delivery and tamoxifen regimen
Ad-Cre-GFP and Ad-empty-GFP were obtained from the Gene Transfer Vector Core, University of Iowa (Iowa City, IA). Six-to 8-week-old mice were exposed to 5Â10 7 plaque-forming unit through nasal inhalation of a calcium phosphate precipitate (5) . Of note, 1 mg/20 g of body weight of tamoxifen was administered orally once per day, starting 7 days after virus inhalation until sacrifice of the mice, except in MYC on/off experiments where tamoxifen treatment was discontinued after 7 days.
Immunoblotting, IHC, immunofluorescence, and microscopic analysis PBS-flushed whole lungs were either fixed in 4% paraformaldehyde and paraffin embedded or snap frozen. Whole protein lysate from PBS-flushed lungs was prepared as described previously (14) . Tissue sections were stained with hematoxylin and eosin (H&E) to determine tissue and tumor morphology. Tumor grades and proliferative status in lung tumor tissues were assessed by a pathologist. Immunostaining was performed on paraffin-embedded tissues according to the protocol described in ref. 11 .
The following antibodies were used for immunoblot analysis and immunostaining: c-MYC (sc-42), CC-10 (sc-9772), SP-C (sc-7706), p16
INK4A (sc-1662), p19 Arf (sc-1066), p21 CIP1 (sc-6246; all from Santa Cruz Biotechnology), ERK1/2 (4695s), and pERK1/2 (4370s) from Cell Signaling Technology, H3K9me3 (07-523, Millipore), Ki67 (SP6, Lab Vision), tubulin (T4026, Sigma), AlexaFluor488 goat anti-rat (A-1106), goat anti-rabbit (A-11008) and rabbit anti-mouse (A-11059; all from Invitrogen), and biotinylated rabbit-anti-mouse (E046401-2) from DAKO.
Fluorescence signals were detected by a laser-scanning microscope (Axiovert 200 M; Zeiss).
For quantitation of nuclear Ki67 signal, tissue sections were scanned with a 3D Histech Panoramic Midi scanner and analyzed with 3D Histech Panoramic Viewer software, using their Nuclear Quant module.
Senescence and apoptosis assays
Lysosomal b-galactosidase activity was assayed on frozen tissue sections as described in ref. 11 . Apoptosis was detected on paraffin-embedded sections with the In Situ Cell Death Detection Kit, Fluorescein (Roche), following the manufacturer's instruction.
Statistical analysis
Data were analyzed with GraphPad Prism software by oneway ANOVA using Bonferonni correction for post hoc tests. Survival between the diverse groups was compared using the log-rank (Mantel-Cox) test. (Fig. 1A and data not shown). This suggests that activation of MYC is not tumorigenic per se within 100 days, but significantly shortens survival of BRAF-induced tumors in a dose-dependent manner even with a modest increase in expression of approximately 2-fold ( Supplementary Fig. S1B ).
Results
MYC
MYC activation results in increased number and size of BRAF V600E -induced lung tumors We observed a 2-fold increase in the lung-to-total body weight ratio in vehicle-treated BM WT/KI mice compared with control (wild-type) B
WT and vehicle-treated M WT/KI lungs ( Supplementary Fig. S1C ). Tamoxifen-treated BM KI/KI and BM WT/KI showed an additional 1.5-fold increase. Furthermore, tamoxifen-treated BM WT/KI and in particular BM KI/KI showed a significantly increased number and size of tumors compared with vehicle-treated BM WT/KI ( Fig. 1B and C), resulting in a higher ratio between the tumor area and the total lung area, as shown by H&E staining of whole lung sections (Fig. 1B) .
When compared with the healthy lungs, surfactant protein-C (SP-C) expression was increased in lungs of tumor-bearing animals, whereas Clara cell antigen expression was reduced ( Supplementary Fig. S1D ). This suggested an AT2PC (alveolar type 2 progenitor cells) phenotype of the tumor, consistent with previously published findings (5). Histopathological analysis showed that the lungs of vehicle-treated BM WT/KI mice variably showed mild bronchiolar hyperplasia, and relatively small, circumscript papillary adenomas. Foci with a more solid growth pattern were occasionally observed (Fig. 1D ), but hallmarks of advanced adenoma (such as nuclear pleiomorphism, prominent nucleoli, mitoses, or necrosis) were rare or absent. Tamoxifen-treated mice exhibited more pronounced bronchiolar hyperplasia and larger adenomas, with accordingly larger areas showing mucoid differentiation and vesicular nuclei, consistent with a bronchiolar component also in these tumors (Fig. 1D) .
Although the tumors were larger, particularly in BM Fig. 2A and B) . Furthermore, foci of trimethylated histone H3 lysine 9 (H3K9me3), yet another marker of senescence, which partially colocalized with p16
INK4A , were also reduced in the tumor areas of tamoxifen treated compared with vehicle-treated BM animals (Fig. 2B) . Moreover, immunoblot analysis of bulk lung lysates showed increased expression of both p16
INK4A and CDKN1A/p21 CIP1 senescence markers in vehicle-treated BM mice compared with control mice, as expected. However, p16
INK4A and p21 CIP1 expression was reduced even below control in tamoxifen-treated BM mice (Fig. 2C) . Expression of the tumor suppressor p19 ARF , which can play a role in either senescence or apoptosis induction depending on the context, was found to be elevated in BM cells irrespective of tamoxifen treatment (Supplementary Fig. S2B ).
Analysis of proliferation status by Ki67 staining showed occasional Ki67 þ cells in tumors of vehicle-treated BM mice, while the percentage of Ki67 þ cells increased strongly after tamoxifen treatment, in particular in BM KI/KI mice (Fig. 2D) . Increased apoptosis was observed in adenomas of tamoxifentreated BM mice, but virtually no apoptotic cells were detected in vehicle-treated BM WT/KI mice ( Supplementary Fig. S2C ).
In conclusion, activation to MYC resulted in suppression of a number of senescence markers and elevated proliferative capacity in parts of BRAF V600E -induced tumors, correlating with accelerated tumor development.
Suppression of p16
INK4A and p21 CIP1 by MYC starts early coinciding with accelerated tumor onset
To assess whether MYC activation affected tumor initiation and senescence suppression already at an early stage, mice were vehicle treated or tamoxifen treated for a period of 7 or 14 days (i.e., 14 and 21 days after virus inhalation) and then sacrificed (Fig. 3A) . H&E staining of lung sections showed that adenoma development had begun already at day 7 after tamoxifen treatment, in particular in BM KI/KI mice (Fig. 3A) . In vehicle-treated BM WT/KI mice, tumors had started to appear at day 14, and the mice displayed lower lung weight as well as lower number and smaller size of tumors when compared with tamoxifen-treated BM KI/KI mice ( Fig. 3A and Supplementary Fig. S3 ). Expression of both p16
INK4A and p21 CIP1 increased in vehicle treated in comparison with tamoxifen-treated mice, where expression of both proteins was suppressed to control levels already 7 days after tamoxifen treatment (Fig. 3B) .
In conclusion, activation of MYC accelerated the onset of BRAF V600E -induced tumors already early after activation coinciding with suppression of BRAF V600E -induced expression of p16 INK4A and p21 CIP1 .
Suppression of p16 INK4A and p21 CIP1 requires continuous MYC activity and is linked to increased tumor size
To investigate the consequence of inactivating MYC during tumor development, we exposed BM WT/KI mice to tamoxifen daily for a period of 7 days (MYC on), after which tamoxifen treatment was discontinued (MYC off) or continued until sacrifice due to disease (Fig. 3C) . Surprisingly, lungs of MYC on/off mice displayed a similar number of tumors to mice under continuous tamoxifen treatment (Fig. 1B and Fig. 3C ) and decreased survival compared with vehicle-treated BM KI/WT mice (data not shown). However, these tumors were of smaller size than those of continuously treated mice, resembling tumor sizes of vehicle-treated BM mice (Figs. 1B and 3C) . Furthermore, the expression levels of p16 INK4A and p21
CIP1
were elevated in the lungs of MYC on/off mice compared with mice under continuous tamoxifen treatment (Fig. 3D ). This suggests that suppression of p16 INK4A and p21 CIP1 requires continuous MYC activity, and that deactivating MYC restores BRAF V600E -induced senescence. This conclusion was further supported by the significant reduction in Ki67 þ cells in tumors of MYC on/off mice compared with those treated daily with tamoxifen (Fig. 2D ).
Discussion
Previous work from our laboratory and others highlighted a function for MYC in suppressing RAS/RAF-induced senescence in vitro (7, 8) . However, whether MYC plays a role in overcoming this OIS barrier in vivo has not yet been determined. To address this question, we utilized a mouse model of BRAF V600E -induced lung adenomas, displaying high levels of senescence-like growth arrest, by which their progression to malignant carcinoma is halted (5) . These mice were intercrossed with mice containing a conditional MycER allele encoding a tamoxifen-regulatable MycER protein (10) . Our results show that MYC activation alone does not give rise to tumors within the 100 days of the experiment, but rather synergizes with BRAF V600E -induced tumorigenesis in a dosedependent manner. This is evidenced by earlier tumor onset, already 7 days after MYC activation. In on/off experiments where MYC activation was discontinued after the first 7 days, we observed an increased number of tumors per lung area, as well as shortened survival compared with BRAF V600E alone. Interestingly, only small adenomas with regained expression of p16 INK4A and p21 CIP1 and strongly reduced Ki67 expression appeared, indicating that continuous MYC activity is required to maintain suppression of senescence. It is, however, not possible to draw conclusions from these data whether MYC not only blocks entry into the senescent state, but also forces cells to exit senescence-a topic that remains to be addressed in the future. Both p16 INK4A and p21 CIP1 are direct target genes repressed by MYC (7), and play a crucial role in blocking malignant progression of BRAF V600E -induced lung adenomas (5) as part of the Rb and p53 senescence pathways, respectively (6) . Furthermore, these two pathways are frequently deregulated in human lung adenocarcinoma (1) . Taken together, these results strongly suggest that suppression of the BRAF V600E -induced senescence-like state by MYC is an important threshold for continued lung tumor growth, thereby increasing the probability of additional oncogenic events. Furthermore, inactivation of MYC in these lesions results in restored BRAF V600E -induced senescence. Surprisingly, MYC did not promote adenoma to carcinoma transition in our model. In contrast, MYC either alone (13) (14) (15) or together with RAF1 (14) induced adenocarcinoma and metastasis in other lung tumor mouse models, however, with much longer latencies (around 60 weeks). Possibly, the massive lung adenoma burden in our model leading to early death through respiratory arrest precludes the onset of malignancy and metastasis. However, we cannot exclude that differences in expression of transgenes, identity of target cells, or functional properties of the different RAS/RAF-family proteins influence the outcome. Importantly, development of MYC-driven adenocarcinoma required additional genetic events to occur, such as activating mutations in KRAS, activation of the STAT pathway, and evasion of apoptosis (13) (14) (15) . Taken together, these observations suggest that suppression of senescence by MYC is a discrete step in tumor development that precedes malignant transformation.
In conclusion, our results show that MYC plays an important synergistic role in lung tumorigenesis by suppressing a BRAF V600E -induced senescence-like state, resulting in increased tumor growth and reduced survival. This is in line with previous reports that MYC depletion induces senescence in vitro in human lung adenocarcinoma and malignant melanoma cells with activating mutations in KRAS, NRAS, or BRAF (8, 16) , and highlights the importance of finding strategies for targeting MYC for cancer therapy, including the new concept of prosenescence therapy (6) . Previous work using mouse tumor models with regulatable MYC or the dominant negative Omomyc has shown that inhibition of MYC often results in complete regression of tumors, frequently as a result of senescence induction (17, 18) . In a Cre-activated KRAS G12D -driven lung adenocarcinoma model, Omomyc caused tumor regression through increased apoptosis and senescence (17) , which is similar to the outcome of MYC inactivation in our model, although we did not observe much apoptosis. The latter may be due to differences in tumor stage, activating oncogenes and/or the preserved endogenous MYC function in our model. In contrast, in a Tet-regulated combined KRAS G12D /MYC mouse model where adenocarcinomas developed after longer latency, it was necessary to inactivate both KRAS and MYC to cause efficient tumor regression (15) . This might be due to accumulation of additional mutations in these tumors as discussed above. Taken together, these findings emphasize the relevance of MYC targeting for lung cancer therapy. In the absence of drugs directly targeting MYC at present time, inhibitors of a number of upstream or downstream targets of the MYC pathway have been suggested, including BET and CDKs (3, 7) . For instance, the senescence-suppression function of MYC is reversed by inhibition of CDK2 (7, 19) . Such therapeutic strategies will be important to explore in the future, potentially in combination with MEK1 or BRAF inhibitors, which has been shown to abrogate tumorigenesis in the BRAF V600E lung tumor model (5) and potently inhibit growth of human lung adenocarcinoma cells with BRAF V600E mutations. Furthermore, these drugs have recently shown promising results in clinical trials for patients with lung cancer carrying this mutation (20, 21) .
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